Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

WishBone Medical, Inc. entered into a U.S. distribution agreement with Implanet


Posted on: 06 Mar 18

WARSAW, Ind., March 06, 2018 (GLOBE NEWSWIRE) -- WishBone Medical. Inc. entered into a U.S. distribution agreement with Implanet to distribute the JAZZ implant system to treat spinal pathologies requiring vertebral fusion surgery in the Orthopedic Market.

The first procedure with WishBone Medical surgeons was completed in early 2018. “We are looking forward to expanding our Orthopedic spine products and the JAZZ system is our first product in this market,” said Nick Deeter, Chairman of the Board and CEO at WishBone Medical.

Mr. Deeter added, “WishBone Medical provides innovative implants and instruments in sterile packed, single use disposable kits and the JAZZ implant system is available in these single use kits.”

Ludovic Lastennet, CEO of Implanet said, “This disruptive single use, sterile packed business model of WishBone Medical compliments the Implanet America JAZZ platform of single use, sterile packed products.”

To learn more about WishBone Medical, visit www.WishBoneMedical.com

About WishBone Medical, Inc.

WishBone Medical is a Global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.

For further information, visit www.WishBoneMedical.com or call Andrew Miclot, Vice-Chairman and President at 574-306-4006.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Euronext™ Growth market in Paris. ALIMP

To learn more about IMPLANET, visit www.Implanet.com

Please contact WishBone Medical at 574-306-4006 or email CustomerService@WishBoneMedical.com for more information.  To learn more about WishBone Medical, visit www.WishBoneMedical.com.

Andrew J. Miclot
Vice Chairman & President
WishBone Medical, Inc.
2150 North Pointe Dr.
Warsaw, IN  46582
(574)306-4006 – Office
(574)527-0964 - Mobile
AndrewMiclot@WishBoneMedical.com

GlobeNewswire
globenewswire.com

Last updated on: 07/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.